| VRTX:Vertex Pharmaceuticals Inc | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
0.90% $4.38
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager |
|
| PR Newswire |
|
WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases. |
| Full Story → |
|
| Headline News |
|
| Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets |
| 10:17a ET January 26 '26 PR Newswire |
|
|
| Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets |
| 12:56p ET January 23 '26 GlobeNewswire |
|
|
| Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize |
| 12:25p ET January 8 '26 PR Newswire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| February 25 '26. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, February 24 '26. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
2.94%
